Financial Daily from THE HINDU group of publications
Thursday, Oct 09, 2003
Financial Daily from THE HINDU group of publications Thursday, Oct 09, 2003 |
|
|
|
|
|
Marketing
-
New Products & Services New painkiller from Intas Pharma Our Bureau
Ahmedabad , Oct. 8 INTAS Pharmaceuticals Ltd (IPL) has developed a new aceclofenac molecule in the analgesic segment in a bid to dent the Rs 244-crore diclofenac product category in pain management. The Ahmedabad-based company, which has set itself a target of Rs 290 crore turnover for the current fiscal, is hoping that the product will do business worth Rs 4 crore in the very first year. The product will be made available in the market under the brand name Hinac. Talking to presspersons, Mr C.P. Kamath, Vice-President (Marketing and Sales), IPL, said this was the first time that such a molecule was developed in India, which for the past two decades was heavily dependent on various diclofenac-based products and would be looking to move on to advanced analgesics that have already established themselves in as many as 26 developed countries. "Our product would be aggressively priced at Rs 19 per strip of 10 tablets as against Rs 23 for a similar number of diclofenac tablets. This is our third foray into the orthopaedic segment in the last four months, the other two being Peroxin, an injectible, and Valoxiv, a drug for rheumatic arthritis. It is our expectation that Hinac would soon make an impact in the geriatric product category, which had hitherto been the fiefdom of molecules that did not see any change over the past two decades," Mr Kamath said. With Voveran from the Novartis stable being the clear leader in the conventional analgesic category with a portfolio worth Rs 62 crore, it may take a while before the aceclofenac drug can chip away at the diclofenac segment. But Intas is betting that the new drug would help it make a foray into the analgesics as it hopes to register a 25 per cent growth over the Rs 220 crore it had posted in the last fiscal.
Article E-Mail :: Comment :: Syndication
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | Home |
Copyright © 2003, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|